CoChat

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer

Open access
Sakellariou-Thompson, Donastas, Forget, Marie-Andrée, Creasy, Caitlin, Bernard, Vincent, Zhao, Li, Kim, Young Uk, Hurd, Mark W., Uraoka, Naohiro, Parra, Edwin Roger, Kang, Ya'an, Bristow, Christopher A., Rodriguez-Canales, Jaime, Fleming, Jason B., Varadhachary, Gauri, Javle, Milind, Overman, Michael J., Alvarez, Hector A., Heffernan, Timothy P., Zhang, Jianhua, Hwu, Patrick, Maitra, Anirban, Haymaker, Cara, Bernatchez, Chantale · 2017 · Clinical Cancer Research
Cited by 60

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Purpose: Survival for pancreatic ductal adenocarcinoma (PDAC) patients is extremely poor and improved therapies are urgently needed. Tumor-infiltrating lymphocyte (TIL) adoptive cell therapy (ACT) has shown great promise in other tumor types, such as metastatic melanoma where overall response rates of 50% have been seen. Given this success and the evidence showing that T-cell presence positively correlates with overall survival in PDAC, we sought to enrich for CD8+ TILs capable of autologous tumor recognition. In addition, we explored the phenotype and T-cell receptor repertoire of the CD8+ TILs in the tumor microenvironment. Experimental Design: We used an agonistic 4-1BB mAb during the initial tumor fragment culture to provide 4-1BB costimulation and assessed changes in TIL growth, phenotype, repertoire, and antitumor function. Results: Increased CD8+ TIL growth from PDAC tumors was achieved with the aid of an agonistic 4-1BB mAb. Expanded TILs were characterized by an activated but not terminally differentiated phenotype. Moreover, 4-1BB stimulation expanded a more clonal and distinct CD8+ TIL repertoire than IL2 alone. TILs from both culture conditions displayed MHC class I-restricted recognition of autologous tumor targets. Conclusions: Costimulation with an anti-4-1BB mAb increases the feasibility of TIL therapy by producing greater numbers of these tumor-reactive T cells. These results suggest that TIL ACT for PDAC is a potential treatment avenue worth further investigation for a patient population in dire need of improved therapy. Clin Cancer Res; 23(23); 7263–75. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-0831

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 60

Metadata

Authors
Sakellariou-Thompson, D., Forget, M.-A., Creasy, C., Bernard, V., Zhao, L., Kim, Y. U., Hurd, M. W., Uraoka, N., Parra, E. R., Kang, Y., Bristow, C. A., Rodriguez-Canales, J., Fleming, J. B., Varadhachary, G., Javle, M., Overman, M. J., Alvarez, H. A., Heffernan, T. P., Zhang, J., Hwu, P., Maitra, A., Haymaker, C., & Bernatchez, C.
Venue
Clinical Cancer Research
Published
2017-11-30
Volume
23
Issue
23
Pages
7263-7275
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2757455370
Cited by
60
References
13
FWCI
1.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-0831
The paper
Sakellariou-Thompson, D., Forget, M.-A., Creasy, C., Bernard, V., Zhao, L., Kim, Y. U., Hurd, M. W., Uraoka, N., Parra, E. R., Kang, Y., Bristow, C. A., Rodriguez-Canales, J., Fleming, J. B., Varadhachary, G., Javle, M., Overman, M. J., Alvarez, H. A., Heffernan, T. P., Zhang, J., . . . Bernatchez, C. (2017). 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-0831

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.